
    
      This Phase 1, multicenter, open-label, study will investigate the safety, pharmacokinetics,
      pharmacodynamics, and preliminary antil-CLL activity of VAY736 in patients with
      relapsed/refractory CLL who have received at least two prior regimens. The study will include
      one arm in the dose escalation phase and two arms in the dose expansion phase.
    
  